pCODR gives initial positive recommendation for Ovarian Cancer Drug

pCODR recently announced their initial positive recommendation for Olaparib (Lynparza), a targeted therapy for ovarian cancer. As part of their recommendation, pCODR stated that “Reimbursement should be for olaparib monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline or somatic as detected by approved testing) high grade serious epithelial ovarian, fallopian tube, or primary peritoneal cancer who have completed at least two previews

Do You have Metastatic Prostate Cancer?

Bayer is conducting a research study in men with metastatic hormone-sensitive prostate cancer. The purpose of this study is to find out if the study drug is safe and effective at keeping prostate cancer under control or slowing the growth of tumors when given in addition to androgen deprivation therapy (ADT) and docetaxel chemotherapy. To be in this study, you must, at a minimum, meet